sales@angenesci.com
Login | Register
logo
Structures Search
Home Other Building Blocks N-Methyl-N-(4-methyl-5-sulfamoylthiazol-2-yl)-2-(4-(pyridin-2-yl)phenyl)acetamide

N-Methyl-N-(4-methyl-5-sulfamoylthiazol-2-yl)-2-(4-(pyridin-2-yl)phenyl)acetamide

CAS No.:
348086-71-5
Catalog Number:
AG00C6EF
Molecular Formula:
C18H18N4O3S2
Molecular Weight:
402.4905
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
1mg
≥98%
1 week
United States
$91
- +
5mg
98%
1 week
United States
$126
- +
10mg
98%
1 week
United States
$154
- +
50mg
98%
1 week
United States
$265
- +
100mg
98%
1 week
United States
$404
- +
Product Description
Catalog Number:
AG00C6EF
Chemical Name:
N-Methyl-N-(4-methyl-5-sulfamoylthiazol-2-yl)-2-(4-(pyridin-2-yl)phenyl)acetamide
CAS Number:
348086-71-5
Molecular Formula:
C18H18N4O3S2
Molecular Weight:
402.4905
MDL Number:
MFCD18633192
IUPAC Name:
N-methyl-N-(4-methyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-(4-pyridin-2-ylphenyl)acetamide
InChI:
InChI=1S/C18H18N4O3S2/c1-12-17(27(19,24)25)26-18(21-12)22(2)16(23)11-13-6-8-14(9-7-13)15-5-3-4-10-20-15/h3-10H,11H2,1-2H3,(H2,19,24,25)
InChI Key:
IVZKZONQVYTCKC-UHFFFAOYSA-N
SMILES:
O=C(N(c1nc(c(s1)S(=O)(=O)N)C)C)Cc1ccc(cc1)c1ccccn1
UNII:
07HQ1TJ4JE
Properties
Complexity:
617  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
402.082g/mol
Formal Charge:
0
Heavy Atom Count:
27  
Hydrogen Bond Acceptor Count:
7  
Hydrogen Bond Donor Count:
1  
Isotope Atom Count:
0
Molecular Weight:
402.487g/mol
Monoisotopic Mass:
402.082g/mol
Rotatable Bond Count:
5  
Topological Polar Surface Area:
143A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
2.1  
Literature
Title Journal
Baseline sensitivity of HSV-1 and HSV-2 clinical isolates and defined acyclovir-resistant strains to the helicase-primase inhibitor pritelivir. Antiviral research 20131101
ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2. The Journal of antimicrobial chemotherapy 20100801
Efficacy of a helicase-primase inhibitor in animal models of ocular herpes simplex virus type 1 infection. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20080201
Herpes simplex virus helicase-primase inhibitors: recent findings from the study of drug resistance mutations. Antiviral chemistry & chemotherapy 20080101
The helicase primase inhibitor, BAY 57-1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB/c mice infected with herpes simplex virus type 1. Antiviral research 20070701
Superior efficacy of helicase-primase inhibitor BAY 57-1293 for herpes infection and latency in the guinea pig model of human genital herpes disease. Antiviral chemistry & chemotherapy 20070101
Antiviral therapies. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20040401
Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293. Antimicrobial agents and chemotherapy 20020601
New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nature medicine 20020401
Properties